At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 75 enrolled
Drug / intervention
hydroxychloroquine/placebodrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicentric Double Blind Versus Placebo Randomised Study Evaluating the Corticosteroid Sparing Effect of Hydrocyschloroquine in Non Complicated Giant Cell Arteritis.
In Brief
A Phase 3 clinical trial evaluating hydroxychloroquine/placebo for Giant Cell Arteritis. Completed, enrolled 75 participants across 23 sites.
Detailed Summary
Cortico-dependence is frequent in giant cell arteritis patients, and no drugs has proved its ability to prevent corticodependence. Hydrocychloroquine is a well tolerated immunomodulatory drug that may have a corticosteroid sparing potential according to immuno-pharmacological and clinical data. We have designed a multcentric double blind versus placebo randomized controled trial to assess the corticosteroid sparing effect of hydroxychloroquine in non complicated giant cell arteritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGiant Cell Arteritis
CountriesFrance
Collaborators--
Timeline
Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2002
Primary CompletionJan 2005
Study CompletionDec 2006
First PostedFeb 2007
TodayJul 2026
First PostedFeb 2, 2007
Enrollment StartJan 1, 2002
Primary CompletionJan 1, 2005
Study CompletionDec 1, 2006
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 19.4 years ago
Interventions
hydroxychloroquine/placebodrug